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Lesch-Nyhan disease is a disorder of purine metabolism resulting from mutations in the gene for
hypoxanthine guanine phosphoribosyl transferase on the X chromosome. It is characterized by
hyperuricemia and all of its consequences, as in gout; but in addition, patients have impressive
disease of the central nervous system. This includes spasticity, involuntary movements, and
retardation of motor development. The behavioral phenotype is best remembered by self-injurious
biting behavior with attendant destruction of tissue. The connection between aberrant metabolism of
purines and these neurologic and behavioral features of the disease is not clear. Increasing evidence
points to imbalance of neurotransmitters. There is increased excretion of the serotonin metabolite
5-hydroxyindoleacetic acid in the urine. There are decreased quantities and activities of a number of
dopaminergic functions. Positron emission tomography scanning has indicated deficiency in the
dopamine transporter. Key words: dopamine, hyperuricemic, hypoxanthine phosphoribosyl
transferase (HPRT), Lesch-Nyhan disease. - Environ Health Perspect 108(suppl 3):409-41 1 (2000).
http.//ehpnetl.niehs.nih.gov/docs/2000/suppl-3/4094 1 lnyhan/abstract.html
Lesch-Nyhan disease is an inborn error of
purine metabolism that has caught the imagi-
nation ofa number ofphysicians and scien-
tists. Initial excitement was relevant to the
facts that a well defined defect in a single
enzyme represented not only the first molecu-
lar disorder ofpurine metabolism to be recog-
nized, but the first biochemical explanation
for at least a subset ofpatients with symptoms
ofgout and the other effects ofhyperuricemia.
However, even casual observation ofpatients
with this disease provides a much largersphere
of interest in terms of potential chemical
understanding ofcerebral function. From the
beginning we were impressed by the idea that
this was an opportunity to define the manner
in which a distinct abnormality in biochem-
istry could lead to stereotyped patterns ofneu-
rologic disease and abnormal behavior. The
disease was described over 30 years ago (1).
The promise is still there. Many questions
have been answered, but many remain to be
elucidated.
Lesch-Nyhan disease is caused by deficient
activity ofthe enzyme hypoxanthine-guanine
phosphoribosyltransferase (HPRT) (2). This
enzyme normally catalyzes the conversion of
hypoxanthine and guanine to their respective
nucleotides, inosinic acid (IMP) and guanylic
acid (GMP). This leads to enormous overpro-
duction ofpurine nucleotides via de novosyn-
thesis and accumulation of uric acid. The
logical results ofthis metabolic abnormality
are hyperuricemia, uricosuria, tophaceous
gout, and urate nephropathy. In addition to
these manifestations, mutations in the HPRT
gene lead to a variable spectrum ofneurologi-
cal and behavioral phenotypes. In the classical
Lesch-Nyhan syndrome patients have striking
neurologic, cognitive, and behavioral abnor-
malities, including self-injurious behavior.
Hyperuricemic variants display only gout or
renal disease and have no neurological abnor-
malities. The neurological variants present an
intermediate picture in which there are motor
and neurological abnormalities, but no abnor-
mal behavior. Enormous progress has been
made in definition ofthe various phenotypes
and the management ofthose aspects ofdis-
ease that are caused by the accumulation of
uric acid. Progress has also been impressive in
the biochemical definition ofthe overproduc-
tion ofpurine by the de novo pathway and by
evidence ofhypoxanthine excess, especially in
the central nervous system. Biochemical
progress has also been evident in recognition
of the enzyme defect in HPRT, and in the
molecular biology ofthe gene and definition
ofthe nature ofmutation. We can expect con-
tinued progress in each ofthese areas. On the
other hand, much remains to be learned. The
relationship ofthe neurological and behavioral
features of the disease has been elusive.
Without a clear understanding offundamen-
tal mechanisms, meaningful interventions into
these important manifestations ofdisease have
not been developed. It is nowhoped that with
the advent ofpowerful new tools for research,
understandings of these interrelations will
emerge, along with better ways to care for
patients.
Lesch-Nyhan disease is a model system for
the elucidation ofrelationships between cogni-
tive development, neurologic function, and
behavior and the biochemistry of the brain.
Implicit is the idea that ifwe could really
understand how these linkages occur, there
would be broad implications forneurobiology.
The disease provides a considerable target
for the development oftreatment ofmanifes-
tations for which there is now little control.
The classic patients display a neurologic pic-
ture that is similar to that ofcerebral palsy.
Muscle tone and deep tendon reflexes are
increased, and there are abnormal movements
such as chorea and athetosis, as well as dysto-
nia. None ofthese patients has learned to walk
and most require assistance in sitting. The
usual appearance ofa patient with this disease
is in a narrow form-fitting wheelchair sup-
ported by a seat belt and a belt around the
chest that permits the patient to participate in
the world around him. Most patients display
considerably more cognitive ability than the
motor defect would imply. Most have speech,
and a few have even had normal intelligence
based on testing. At least one ofour patients
has succeeded in a normal school curriculum.
Two patients have graduated from high
school. The testing ofintelligence is so com-
plicated by the behavior ofthese patients that
most testing is doubtless inaccurate. A patient
who, when presented with written words or
images on pages, cannot resist an urge to tear
them out ofthe book or throw them on the
floor or at the examiner makes for a difficult
test object. These behavioral features of the
disease are uniform in the classic disease. The
best known ofthese manifestations is the self-
injurious behavior; the most common ofthese
behaviors is biting, which leads to loss oftis-
sue around the lip and partial amputation of
the tongue. Those who do not bite themselves
tend to indulge in other self-injurious behav-
iors, such as head-banging or bruising the chin
on a hard surface. These patients have normal
pain sensation and regularly display evidence
of this when they injure themselves. They
sleep poorly and often keep the entire family
awake until methods are developed for protec-
tion against mutilation when family members
are asleep. Patients also have aggressive behav-
ior directed against others, limited largely by
the limitation imposed by the motor defect.
Most patients vomit, and there have been
complicating esophageal ulcers or anemia
from chronic blood loss, as well as acute hem-
orrhage. This also tends to get incorporated
into behavior as a form ofaggression.
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Neuropathogenesis
The manner in which the abnormality in
purine metabolism causes the neurologic and
behavioral characteristics ofthe classic disease
has not been established, but there is a variety
ofevidence that this has to do with an abnor-
mality in neurotransmitter balance. A rela-
tionship to serotonin was first suggested by
studies of aggressive muricidal behavior in
animals with significantly lower contents of
serotonin in the brain. The administration of
5-hydroxytryptophan, an immediate precur-
sor of serotonin, statistically significantly
reduced this aggressive behavior (3). In
Lesch-Nyhan patients the excretion of
5-hydroxy-indoleacetic acid in the urine (4)
was significantly increased. This might mean
that the amounts ofserotonin in the brain
were low. The administration of 5-hydrox-
ytryptophan and carbidopa in conjunction
with imipramine to increase levels of sero-
tonin (5) abolished the self-injurious behavior.
This was a very rewarding result, although it
was disappointing in that it was always tempo-
rary. In general, the effects lasted only a few
weeks and could not be reobtained by a fur-
ther administration ofthe compounds.
Evidence for abnormality in dopamine
neurotransmitter function has come from
positron emission tomography (PET), in
which ligands that bind to dopamine-related
proteins in the brain have been used. The ear-
liest studies used compounds that bound to
dopamine DI or D2 receptors in the basal
ganglia. These studies provided nice pictures
in which the appearance of the basal ganglia
was highlighted. However, quantitative data
did not reveal important differences in these
receptors in Lesch-Nyhan patients versus con-
trols. Ernst et al. (6) studied this system by
the administration of 18F-dopa, which per-
mits external imaging by PET and provides a
measure of the activity of the dopa decar-
boxylase enzyme and hence of neuronal
dopamine activity. They found a striking
decrease in Lesch-Nyhan patients compared
to controls.
The most compelling evidence from PET
scanning has come from work ofWong et al.
(7), who used the ligand ['1C]WIN 35,428,
which binds specifically to dopamine trans-
porters. In these studies of 6 patients, there
was as much as a 75% reduction ofdopamine
transporter in putamen and as much as 63%
in caudate compared to 10 control individu-
als and 3 patients with Rett syndrome. These
data are consistent with a reduced density of
dopamine containing neurons or terminals.
These investigators also studied volumetric
magnetic resonance imaging in the same indi-
viduals and found that caudate volume was
reduced by 30%. Correction for volume
reduction gave a figure for an even greater
decrease in the caudate-to-cerebellum ratio of
binding to dopamine transporters. These
studies are strong evidence for alteration in
dopaminergic systems in the Lesch-Nyhan
disease.
These data are consistent with the pio-
neering work on neurotransmitters reported
by Lloyd et al. in 1981 (8). These investiga-
tors studied the brains postmortem ofthree
patients with the Lesch-Nyhan disease who,
like previously autopsied patients, displayed
no morphological abnormalities. Control
material was obtained postmortem from the
brains ofage-matched patients who had no
evidence ofneurologic disease (n = 8). Studies
of neurotransmitter biochemistry revealed
that dopaminergic function in the caudate,
putamen, nucleus accumbens, and external
pallidum was significantly lower in patients
than in controls. It was impressive that signif-
icant differences could be obtained in a series
in which the number ofpatients was as low as
three, giving credence to the significance of
these findings. Values in the patient ranged
from 10 to 30% of the control values. The
low levels included those ofdopamine itself,
homovanillic acid (HVA), dihydroxyphenyl-
alanine decarboxylase, and tyrosine hydroxy-
lase. The deficits in dopamine function were
not as severe as those seen in Parkinson dis-
ease, but they were significantly different
from controls.
In the same study, data on norepinepherine
and serotonin function were not significantly
different in the brains of the patients. The
activity ofdopamine 3-hydroxylase was not
decreased in the hypothalamus, and that is
significant because alterations in this enzyme
have previously been reported in the plasma
ofsome patients. The levels ofserotonin were
slightly increased and significantly so in the
putamen. 5-Hydroxyindolacetic acid was also
elevated there, as well as in the pallidum, so
these data were consistent with our findings
in the urine ofpatients with this disease. The
data on serotonin and norepinepherine high-
light the specificity of the observations on
dopaminergic function.
Similarly, we studied the concentrations
of HVA in the cerebrospinal fluid in a
patient with this disease and found that the
level was low (9). A more elaborate study was
reported by Silverstein et al. (10). They
pointed out that concentrations in cere-
brospinal fluid of HVA and 5-hydroxyin-
dolacetic acid undergo age-related changes.
There is a rapid fall in the first 3 years oflife
and then a more gradual fall through adoles-
cence. Accordingly, they did serial measure-
ments of cerebrospinal fluid HVA in 4
patients over a 5-year period with an age
range of 1.5-17 years, and they compared
these data with age-related data on 94 con-
trols. The values for the Lesch-Nyhan
patients were lower than the mean for age in
18 of 19 samples tested, and 10 samples fell
below the range found in controls.
The hypothesis that dopamine is related to
self-injurious behavior received support by the
development ofa rat model by Breese et al.
(11). They used 6-hydroxydopamine (6-
OHDA), which destroys catecholamine-
containing neurons in the brain. Treatment of
adult animals makes them sensitive to a num-
berofbehaviors on the administration ofdopa
or a dopa agonist. Treatment ofnewborn ani-
mals leads to self-injurious behavior in
response to a dopa agonist. This change in
sensitivity was a long-lasting effect ofneonatal
treatment with 6-OHDA. As long as that
compound was given in the neonatal period,
the dopa agonist could be given even in adult-
hood and the self-injurious response was
observed. In one series, 0 of20 control ani-
mals exhibited dopa-induced self-injurious
behavior. Similarly, 0 of 18 animals given
6-OHDA as adults, and 39 of60 treated in
the neonatal period with 6-OHDA, exhibited
self-injurious behavior, ahighlysignificantdif-
ference. There were also dose-effect relation-
ships. In the neonatally treated animals, the
greater the dose ofdopa or dopa agonist, the
greater the percentage ofanimals exhibiting
self-injurious behavior.
Breese et al. (11) conducted pharmacolog-
ical studies in which D2 or mixed DI-D2
receptor antagonists such as haloperidol and
flupentixol had some effect in blocking the
self-injurious response to dopa. On the other
hand, there was virtually complete inhibition
of this response when the Dl antagonist
Sch-23390 was used. Unfortunately, to date
none of the D1 or D2 antagonists that have
been used in Lesch-Nyhan patients have been
effective in the management of their self-
injurious behavior.
Other Disease Models
The basal ganglia are increasingly recognized
as a target for the adverse effects ofmetabolic
disease. Haas et al. (12) reported experience
with an 8-year-old girl with propionic
acidemia who was in excellent metabolic con-
trol, and was in hospital after receiving inten-
sive treatment for pancreatitis such that her
levels of the abnormal metabolites in the
urine were lower than they had ever been.
Nevertheless, as she was being prepared for
discharge she became suddenly aphasic, expe-
rienced complete infarction ofher basal gan-
glia, and died within a few days. A review of
our only other patient on whom an autopsy
had been done after death from propionic
acidemia revealed lesions in the basal ganglia
in which there was neuronal loss.
More recently, we reported (13) on two
other patients in whom propionic acidemia
had a more indolent presentation than in the
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usual patient (the usual patient has acute
life-threatening episodes ofketoacidosis that
at least call attention to the disease). These
patients instead presented first neurologi-
cally. On first examination, one of the
patients appeared to be a typical Lesch-
Nyhan patient. He was wheelchair-bound
and had a combination ofathetoid and dys-
tonic movements that were typical of his
basal ganglia disease. However, he had no
abnormalities in behavior and his metabolic
disease appeared to be static at that time. We
had not seen the second patient, although a
diagnosis of propionic acidemia was made
for the first time after the age of20. Our first
encounter with the second patient was a
blood sample that was sent to the laboratory
for HPRT analysis because he not only had a
diagnosis of athetoid cerebral palsy, but he
had destructively bitten his lower lip. The
HPRT was normal, and we suggested send-
ing blood and urine for further metabolic
studies. Further studies found methylcitrate
and the other organic acids typical ofpropi-
onic acidemia, and enzymatic analysis
revealed a severe deficiency of propionyl
CoAcarboxylase.
In seeking models for abnormalities in
dopaminergic systems we have begun to
look at patients with abnormalities in
biopterin synthesis (14). Patients with these
abnormalities first became recognized with
the programs of neonatal screening for
phenylketonuria. It became apparent that
there was a subset of patients uncovered by
neonatal screening programs that, despite
excellent compliance with the diet and nor-
mal levels ofphenylalanine after treatment,
went on to develop severe mental retarda-
tion. A number of these disorders reflect
various steps in the synthesis oftetrahydro-
biopterin or BH4, which is the essential
cofactor of the phenylalanine hydroxylase
reaction (14). The importance from the
dopamine point ofview is that BH4 is also
the cofactor for the tyrosine hydroxylase
reaction in the synthesis of dopa, and,
hence, dopamine. In the first step of this
reaction, the guanosine triphosphate (GTP)
reaction is severely deficient in patients
homozygous for mutations in this gene; they
have the typical so-called malignant hyper-
phenylalaninemia resulting from abnormali-
ties in biopterin metabolism. Other patients
have since been identified that have clinical
generalized dystonia that is inherited in
autosomal dominant fashion and is respon-
sive to low doses ofdopa (15). Patients with
this syndrome have mutations on one of
their two genes on chromosome 14q. Many
males in affected families are asymptomatic
even though they carry the mutation,
whereas females tend to develop clinical dys-
tonia. An intermediate syndrome has
recently been discovered in families with
dopa-responsive dystonia in which children
who are heterozygous for two different
mutations in the cyclohydrolase gene have a
syndrome markedly dystonic and somewhat
responsive to dopa intermediate between the
classic autosomal recessive cyclohydrolase
deficiency and the dopa-responsive domi-
nant dystonia. These patients seem to do
better when treated with tetrahydrobiopterin
as well as with dopa.
A relationship between deficiency of
HPRT and its potential shortages of IMP
and GMP and its di- and tri-nucleotides
could be through a requirement for GTP in
signal transduction through the dopamine
receptor-agonist interaction (16-18).
Alternatively, there could be defective syn-
thesis oftetrahydrobiopterin, as in the GTP
cyclohydrolase deficiency dopa-responsive
dystonia, leading to a shortage ofdopamine
in the basal ganglia.
In summary, there is substantial evidence
relevant to dopamine and the Lesch-Nyhan
disease. I am hopeful that with time we will
be able to make the appropriate connections
between neurotransmitter interrelations and
mutation in the HPRTgene. I am hopeful
that all of this will lead to a more effective
means oftreatment in Lesch-Nyhan disease.
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